Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Neovii Biotech
Modality
monoclonal_antibody
Development Phase
Phase 2/3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
46Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00836654CT.gov Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Epithelial Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Catumaxomab (this asset) | Neovii Biotech | P2/3 | B · 61 |
| Sorafenib | Shandong Cancer Hospital and Institute | P3 | BB |
| Pembrolizumab | Sheba Medical Center | P2 | B |
| Enadenotucirev | Akamis Bio | P1/2 | B |
| Linifanib | Abbott | P3 | B |
| Adriamycin | University Health Network, Toronto | P2 | CCC |
| Abemaciclib | University Health Network, Toronto | P2 | CCC |
| Lenvatinib | Sheba Medical Center | P2 | CCC |
| Olaparib | Xiaoxiang Chen | P2 | CCC |
+28 more in the Epithelial Neoplasm cohort
Other indications for Catumaxomab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Fallopian Tube Neoplasm | — | P2 | B · 57 |
| Peritoneal Neoplasm | — | P2 | B · 57 |
| Ovarian Carcinoma | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Catumaxomab in Epithelial Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/catumaxomab-epithelial-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →